Use of estriol for treatment of climacteric osteoporosis
First Claim
Patent Images
1. A method of treating climacteric osteoporosis comprising continuously transdermally administering from 5 to 25 mg per day of estriol as the sole active ingredient to a person in need of same for at least 24 hours.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.
5 Citations
4 Claims
- 1. A method of treating climacteric osteoporosis comprising continuously transdermally administering from 5 to 25 mg per day of estriol as the sole active ingredient to a person in need of same for at least 24 hours.
Specification